Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  European Journal of Pharmacology

• Publication date

  1995-02-06

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0014-2999(94)00682-WPMID 7737328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved Therapy of Parkinson's Disease with Tolcapone, a Central and Peripheral COMT Inhibitor with an S‐Adenosyl‐L‐Methionine‐Sparing Effect

  1994cited by this paper
• Comparison of two new inhibitors of catechol O‐methylation on striatal dopamine metabolism: a microdialysis study in rats

  1994cited by this paper
• Crystal structure of catechol O-methyltransferase

  1994cited by this paper
• Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.

  1993cited by this paper
• Effects of Catechol‐O‐Methyltransferase Inhibitors and L‐3,4‐Dihydroxyphenylalanine With or Without Carbidopa on Extracellular Dopamine in Rat Striatum

  1993cited by this paper
• Catechol‐O‐methyltransferase inhibition increases striatal L‐dopa and dopamine

  1992cited by this paper
• Different in vivo properties of three new inhibitors of catechol O‐methyltransferase in the rat

  1992cited by this paper
• Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

  1992cited by this paper
• Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.

  1992cited by this paper
• Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters.

  1992cited by this paper
• Extracellular Concentrations of Dopamine and Metabolites in the Rat Caudate After Oral Administration of a Novel Catechol‐O‐Methyltransferase Inhibitor Ro 40–7592

  1992cited by this paper
• New Therapeutic Strategies in Parkinson’s Disease: Inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592

  1991cited by this paper
• Interstitial 3‐Methoxytyramine Reflects Striatal Dopamine Release: An In Vivo Microdialysis Study

  1991cited by this paper
• Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form.

  1991cited by this paper
• Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats.

  1990cited by this paper
• New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

  1989cited by this paper
• Clinical Pharmacokinetics of Anti-Parkinsonian Drugs

  1987cited by this paper
• Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release.

  1987cited by this paper
• The pharmacology of Parkinson's disease: Basic aspects and recent advances

  1984cited by this paper
• Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites

  1984cited by this paper
• Pharmacokinetics of levodopa.

  1984cited by this paper
• Distinct Cellular Localization of Membrane‐Bound and Soluble Forms of Catechol‐O‐Methyltransferase in Brain

  1983cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• 3‐O‐Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway

  1982cited by this paper
• Catechol-O-methyl transferase: pharmacological aspects and physiological role.

  1975cited by this paper
• Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.

  1972cited by this paper
• The metabolism of L‐3–0‐methyldopa, aprecursor of dopa in man

  1971cited by this paper
• J. METHYLATION REACTIONS IN THE FORMATION AND METABOLISM OF CATECHOLAMINES AND OTHER BIOGENIC AMINES

  1966cited by this paper

• A systematic review of the cognitive effects of the COMT inhibitor, tolcapone, in adult humans

  2024cites this paper
• Limiting Monoamines Degradation Increases L-DOPA Pro-Locomotor Action in Newborn Rats

  2023cites this paper
• Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease

  2020cites this paper
• Effects of COMT genotype and tolcapone on lapses of sustained attention after sleep deprivation in healthy young men

  2018cites this paper
• Effects of catechol-O-methyltransferase on reinforcement learning and mesolimbic dopamine transmission

  2015cites this paper
• Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment

  2010cites this paper
• The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator

  2010cites this paper
• Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.

  2010cites this paper
• Medical Management of Parkinson’s Disease

  2009cites this paper
• HIV-1 Tat Protein-Induced Rapid and Reversible Decrease in [3H]Dopamine Uptake: Dissociation of [3H]Dopamine Uptake and [3H]2β-Carbomethoxy-3-β-(4-fluorophenyl)tropane (WIN 35,428) Binding in Rat Striatal Synaptosomes

  2009cites this paper
• The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats

  2009cites this paper
• HIV-1 Tat Protein-Induced Rapid and Reversible Decrease in [ 3 H]Dopamine Uptake: Dissociation of [ 3 H]Dopamine Uptake and [ 3 H]2 (cid:1) -Carbomethoxy-3- (cid:1) -(4-fluorophenyl)tropane (WIN 35,428) Binding in Rat Striatal Synaptosomes

  2009cites this paper
• HIV-1 Tat protein-induced rapid and reversible decrease in [ 3 H ] dopamine uptake : dissociation of [ 3 H ] dopamine uptake and [ 3 H ] WIN 35 , 428 binding in rat striatal synaptosomes

  2009cites this paper
• Computational Systems Analysis of Dopamine Metabolism

  2008cites this paper
• [Tolcapone in the management of Parkinson's disease].

  2007cites this paper
• Tolcapone in the management of Parkinson’s disease

  2006cites this paper
• Tolcapone

  2005cites this paper
• The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.

  2005cites this paper
• Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.

  2003cites this paper
• Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

  2003cites this paper
• BIA 3-202, a Novel Catechol-O-Methyltransferase Inhibitor, Reduces the Peripheral O-Methylation of L-DOPA and Enhances Its Availability to the Brain

  2003cites this paper
• Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson’s disease

  2003cites this paper
• 18F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

  2002cites this paper
• Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.

  2002cites this paper
• Brain catecholamine metabolism in catechol‐O‐methyltransferase (COMT)‐deficient mice

  2002cites this paper
• Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.

  2001cites this paper
• BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.

  2001cites this paper
• A preclinical re-evaluation of the safety profile of tolcapone.

  2001cites this paper
• Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

  1999cites this paper
• Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.

  1999cites this paper
• Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake.

  1999cites this paper
• Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

  1999cites this paper
• Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons.

  1999cites this paper
• Tolcapone, a Selective Catechol‐O‐Methyltransferase Inhibitor for Treatment of Parkinson's Disease

  1999cites this paper
• New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

  1999cites this paper
• Extending levodopa action

  1998cites this paper
• A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

  1998cites this paper
• Effect of subchronic administration of tolcapone on L-DOPA-and carbidopa-induced release of striatal dopamine and its metabolites

  1998cites this paper
• Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats.

  1998cites this paper
• Influence of COMT inhibition on levodopa pharmacology and therapy

  1998cites this paper
• Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa

  1998cites this paper
• Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

  1998cites this paper
• Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.

  1997cites this paper
• Emerging treatments in Parkinson's disease.

  1997cites this paper
• Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

  1997cites this paper
• Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations

  1997cites this paper
• Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.

  1997cites this paper
• Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L‐DOPA: On the role of benserazide pretreatment

  1997cites this paper